PFKP silencing suppresses tumor growth via the AXL-MET axis

文献类型： 外文期刊

第一作者： Zhao, Huijie

作者： Zhao, Huijie;Cai, Jing;Zhao, Huijie;Sun, Yuze;Liu, Yue;Li, Yu;Chen, Sijie;Zhou, Zhiqing;Du, Yuhui;Zeng, Xiaofei;Chen, Guoan;Sun, Yuze;Mei, Qi;Zeng, Xiaofei;Ren, Huan;Su, Wenmei;Mei, Qi;Chen, Guoan

作者机构：

关键词： lung cancer; glycolysis; PFKP; AXL; MET

期刊名称：INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES （ 影响因子：10.0； 五年影响因子：9.6 ）

ISSN： 1449-2288

年卷期： 2024 年 20 卷 15 期

页码：

收录情况： SCI

摘要： PFKP (Phosphofructokinase, Platelet Type isoform), as an essential metabolic enzyme, contributes to the high glycolysis rates seen in cancers while its role in oncogenic pathways, especially from a non-metabolic aspect, is not fully understood. We found that PFKP was highly expressed in NSCLC and was related to poor patient survival. Knockdown of PFKP significantly inhibited cell proliferation, colony formation, invasion, and migration of NSCLC cells. Nanoparticles-mediated PFKP silencing can inhibit tumor growth in vivo. Mechanistically, we found that PFKP can bind with AXL and promote its phosphorylation at Y779, thus activating the AXL signaling pathway and promoting MET phosphorylation. In addition, several glycolysis, glutaminolysis, and TCA cycle proteins were downregulated following PFKP silencing. PFKP has an oncogenic role in cancer progression in vitro and in vivo. Beyond its known role in glycolysis, PFKP also has a non-metabolic function in affecting lung cancer progression by interacting with the AXL-MET axis, thus indicating a potential therapeutic target for lung cancer.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序